A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinoconjunctivitis

Trial Profile

A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinoconjunctivitis

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2011

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Allergic conjunctivitis; Allergic rhinitis; Rhinoconjunctivitis
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top